UK HealthCare and Cincinnati Children's Hospital Medical Center have signed a Letter of Intent (LOI) to move toward a significant partnership to provide pediatric heart care services in the region.

Students and Faculty in the Department of Toxicology and Cancer Biology held an Open House in August to meet with incoming first year graduate students. Oral and poster presentations highlighted the varied research programs in the department that investigate basic, translational and clinical aspects of toxicology and cancer biology.

The Exatherm Total Body Hyperthermia System heats the patient’s blood to potentially damage or kill lung cancer cells throughout the body. UK is the only site in the country approved to test this new treatment in advanced lung cancer patients.

LEXINGTON, Ky. (Sept.

NIH Public Access Policy
Reference List

 Overview:

Congratulations to our new UK AOA inductees; including our very own Dustin Stevens!

LEXINGTON, Ky. (Aug. 28, 2015) – The Food and Drug Administration (FDA) approved clinical trials for an investigational cancer treatment pioneered by University of Kentucky researchers in the Department of Surgery.
The Exatherm Total Body Hyperthermia System (Exatherm-TBH) was developed at UK in a public-private partnership with Exatherm, LLC, explained medical researcher Cherry Ballard-Croft, Ph.D. The project received grant funding from the National Institutes of Health.